Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Sally Agersborg"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/d6273eb2bf8d46d182472d0cc9da5701
Autor:
Fernando Lopez-Diaz, Steven Rivera, Christophe Magnan, Brad Thomas, Yanglong Mou, Segun Jung, Sally Agersborg, Vincent Funari
Publikováno v:
Cancer Genetics. :30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ef3de099eb7e765bc52c321816cb5dd
https://doi.org/10.1016/j.cancergen.2022.10.098
https://doi.org/10.1016/j.cancergen.2022.10.098
Autor:
Madhuri Paul, Frank J. Scarpa, Rachel Daringer, Sally Agersborg, Vincent Anthony Funari, Forrest Blocker
Publikováno v:
Cancer Research. 82:2934-2934
Purpose: Aberrant PI3K pathway activation drives tumor proliferation and survival. The aim of this study was to identify PI3K pathway activation patterns in endometrial cancer by profiling mutational prevalence and co-mutation with PTEN and TP53. Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f257c6e2a8837184b687f0d2636d8446
https://doi.org/10.1158/1538-7445.am2022-2934
https://doi.org/10.1158/1538-7445.am2022-2934
Autor:
Frank J. Scarpa, Madhuri Paul, Rachel Daringer, Sally Agersborg, Vincent A. Funari, Forrest J. Blocker
Publikováno v:
Cancer Research. 82:2281-2281
Background: AML with RUNX1 mutation is a provisional entity in the WHO classification. RUNX1 variants generally consist of truncating mutations throughout the gene, as well as SNVs, insertions, and deletions in the RUNT domain. In the germline settin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66d3e56516275d1bff3d4e8030067cbf
https://doi.org/10.1158/1538-7445.am2022-2281
https://doi.org/10.1158/1538-7445.am2022-2281
Autor:
Miyoung Shin, Paris Petersen, Steven Lau-Rivera, Segun Jung, Sally Agersborg, Jacyln Hechtman, Fernando Lopez-Diaz, Vincent Funari
Publikováno v:
Cancer Research. 82:1254-1254
Background: Incorporating gene fusions into a comprehensive profile is critical not only because very effective therapies targeting oncogenic fusion proteins exist but they may also negate the response to therapy of an actionable SNV and InDel mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::948ea3444775128c365b058818ea78e6
https://doi.org/10.1158/1538-7445.am2022-1254
https://doi.org/10.1158/1538-7445.am2022-1254
Autor:
Rolf Muller, Kay Yeung, Stephenie Jones, Christopher Brandt, Vincent Anthony Funari, Sally Agersborg, Judy Muller-Cohn, Janet Dickerson
Publikováno v:
Journal of Clinical Oncology. 40:e13016-e13016
e13016 Background: Overexpression of HER2 serves as an oncogenic driver in breast cancer which can result in tumor progression and distant metastases. Amplification or overexpression of HER2 occurs in approximately 15–30% of breast cancers and serv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b317034b7f27da11e7c73e5d7b02d30c
https://doi.org/10.1200/jco.2022.40.16_suppl.e13016
https://doi.org/10.1200/jco.2022.40.16_suppl.e13016
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background PD-L1 expression and Tumor Mutation Burden (TMB) have independently emerged as prospective biomarkers of response to anti PD1-/PDL1 checkpoint inhibitors and even combined use of TMB, PD-L1 protein levels has been proposed. However, how th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::015023c63b6b1682a1948bdd8c258784
https://doaj.org/article/d6273eb2bf8d46d182472d0cc9da5701
https://doaj.org/article/d6273eb2bf8d46d182472d0cc9da5701
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
Autor:
Sally Agersborg, Shiping Jiang, Robert Gasparini, Christopher Mixon, Gregory Hess, Sramila Aithal, Thanh Nguyen, Sucha Sudarsanam, Lawrence M. Weiss, Maher Albitar, Forrest Blocker, Wayne Chen
Publikováno v:
Breast Cancer Research and Treatment
Purpose While HER2 testing is well established in directing appropriate treatment for breast cancer, a small percentage of cases show equivocal results by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Alternative probes ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eeb76163463a3027d3bc418e30d657f
https://doi.org/10.1007/s10549-018-4755-5
https://doi.org/10.1007/s10549-018-4755-5
Autor:
Sucha Sudarsanam, Maher Albitar, Shiping Jiang, Sally Agersborg, Wanlong Ma, Vincent Funari, Wayne Chen, Forrest Blocker
Publikováno v:
Oncotarget. 9:13682-13693
// Maher Albitar 1 , Sucha Sudarsanam 1 , Wanlong Ma 1 , Shiping Jiang 1 , Wayne Chen 1 , Vincent Funari 1 , Forrest Blocker 1 and Sally Agersborg 1 1 NeoGenomics Laboratories, Aliso Viejo, CA, USA Correspondence to: Maher Albitar, email: maher.albit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab1f3efab3980d79db8fbcb50cab2455
https://doi.org/10.18632/oncotarget.24455
https://doi.org/10.18632/oncotarget.24455
Autor:
Ryan Bender, Segun C Jung, Christophe Magnan, Vincent Funari, Sally Agersborg, Fernando J. Lopez-Diaz, Hyunjun Nam
Publikováno v:
Blood. 138:3994-3994
Background: Aneuploidy and large-scale Copy Number Variations (CNVs) are prominent features of cancer cells. While Fluorescence in situ hybridization (FISH) and conventional cytogenetics (CC) are the gold standard for detecting aneuploidy and CNVs, N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0104d59def7949cb0de84871a6b61f42
https://doi.org/10.1182/blood-2021-150911
https://doi.org/10.1182/blood-2021-150911